Trip killer

A trip killer is a drug that aborts or reduces the effects of a hallucinogenic drug experience (or 'trip').[1][2][3][4][5][6][excessive citations] Examples, in the case of serotonergic psychedelics, such as LSD, psilocybin, mescaline, and dimethyltryptamine (DMT), include serotonin receptor antagonists like antipsychotics and certain antidepressants, benzodiazepines, and various other drugs.[4][7] Trip killers are often used by recreational psychedelic users as a form of harm reduction to manage so-called bad trips, for instance difficult experiences with prominent anxiety.[2][4] Although trip killers exist for certain types of hallucinogens, antidotes do not exist for all types of hallucinogens, for instance dissociatives like phencyclidine (PCP).[3]

The most commonly encountered putative trip killers in a 2024 online study of Reddit social media postings were the benzodiazepines alprazolam and diazepam, the antipsychotic quetiapine, the antidepressant trazodone, and alcohol.[4][5][6]

Drugs that have been formally assessed and shown in clinical studies to completely block or reduce the effects of serotonergic psychedelics include the serotonin 5-HT2A receptor antagonists ketanserin and risperidone.[7][8][9][10][11][12][13][excessive citations]

Benzodiazepines are anxiolytics and may be useful in reducing anxiety with hallucinogens, including clinically.[3][14] High-dose niacin (vitamin B3) was reported to reduce and block the effects of LSD in one study, but subsequent research found that it was ineffective.[7][15][16]

While used for harm-reduction purposes, combining hallucinogens with trip killers is not fully characterized and might pose medical risks.[1][2][4][5][6][excessive citations]

  1. ^ a b Muir OS, Shinozuka K, Beutler BD, Arenas A, Cherian K, Evans VD, Fasano C, Tabaac BJ (2024). "Psychedelic Therapy: A Primer for Primary Care Clinicians-The Strengths, Weaknesses, Opportunities, and Threats of Psychedelic Therapeutics" (PDF). Am J Ther. 31 (2): e178–e182. doi:10.1097/MJT.0000000000001720. PMID 38518273. When psychedelics are used in recreational contexts without adequate supervision, they can lead to tragic outcomes.20 There are rare reports of serious adverse effects, including psychosis and even suicide, arising from recreational use.21 Methods for subduing socalled "bad trips" in recreational settings include potentially dangerous habits, such as taking benzodiazepines, which are known to be "trip killers."22
  2. ^ a b c Bellanavidanalage Gothami Ayanthie Vis Jayasinha (8 February 2024). Towards Safer Trips: Exploring Harm Reduction Strategies for Recreational Psychedelic Use in Aotearoa New Zealand (Thesis). University of Otago. Retrieved 3 October 2024. Another form of mixing substances involves the use of trip killers; a pharmacological coping strategy aimed to reduce the negative effects of a psychedelic experience by consuming a different substance (Suran, 2024). While this is a new concept and an under researched area, there are reports of trip killers being effective in reducing the negative effects of a psychedelic experience (Suran, 2024). One study gathered research from reddit, an online social media platform, investigating the usage of trip killers during challenging psychedelic experiences (Suran, 2024). The most popular and effective trip killers used were prescription medication, with 47% reporting the use of benzodiazepines as they reduce anxiety, followed by the use of antipsychotic and antidepressant medication (Suran, 2024). However, there are risks in mixing substances with psychedelic drugs, and subjectivity in the effectiveness. As some individuals may experience positive effects, while for others it may lead to negative effects (Suran, 2024). Therefore, it is recommended that before using trip killers, individuals should try other non- pharmacological coping strategies to reduce the negative effects of the psychedelic drug (Gable, 2004; Van Amsterdam et al., 2011). These factors discussed above, demonstrate the effectiveness of protective behaviours and harm reduction practices, in promoting safe psychedelic use and reducing harm.
  3. ^ a b c Leikin, Jerrold B.; Krantz, Anne J.; Zell-Kanter, Michele; Barkin, Robert L.; Hryhorczuk, Daniel O. (1989). "Clinical Features and Management of Intoxication Due to Hallucinogenic Drugs". Medical Toxicology and Adverse Drug Experience. 4 (5). Springer Science and Business Media LLC: 324–350. doi:10.1007/bf03259916. ISSN 0113-5244.
  4. ^ a b c d e Yates G, Melon E (January 2024). "Trip-killers: a concerning practice associated with psychedelic drug use". Emerg Med J. 41 (2): 112–113. doi:10.1136/emermed-2023-213377. PMID 38123961.
  5. ^ a b c Suran M (February 2024). "Study Finds Hundreds of Reddit Posts on "Trip-Killers" for Psychedelic Drugs". JAMA. 331 (8): 632–634. doi:10.1001/jama.2023.28257. PMID 38294772.
  6. ^ a b c Davidson, Colin (14 February 2024). "Using "trip killers" to cut short bad drug trips is potentially dangerous". The Conversation (UK Edition). SyndiGate Media Inc.: NA–NA. Retrieved 3 October 2024.
  7. ^ a b c Halman A, Kong G, Sarris J, Perkins D (January 2024). "Drug-drug interactions involving classic psychedelics: A systematic review". J Psychopharmacol. 38 (1): 3–18. doi:10.1177/02698811231211219. PMC 10851641. PMID 37982394.
  8. ^ Halberstadt, Adam L.; Nichols, David E. (2020). "Serotonin and serotonin receptors in hallucinogen action". Handbook of Behavioral Neuroscience. Elsevier. p. 843–863. doi:10.1016/b978-0-444-64125-0.00043-8. ISSN 1569-7339.
  9. ^ Canal CE (2018). "Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action". Handb Exp Pharmacol. 252: 227–260. doi:10.1007/164_2018_107. PMC 6136989. PMID 29532180. Reports from clinical trials conclude that the psychedelic effects of psilocybin and LSD are mediated by 5-HT2A receptors, because they are blocked by ketanserin (40 mg, P.O.), typically viewed as a selective 5-HT2A antagonist (Kometer et al. 2012; Kraehenmann et al. 2017; Preller et al. 2017; Quednow et al. 2012). Haloperidol, typically viewed as a selective dopamine D2 antagonist, is much less effective than ketanserin at blocking psilocybin's effects, but risperidone, an antipsychotic with combined D2/5-HT2 activity, is as effective as ketanserin (Vollenweider et al. 1998).
  10. ^ Husain MI, Blumberger DM, Castle DJ, Ledwos N, Fellows E, Jones BD, Ortiz A, Kloiber S, Wang W, Rosenblat JD, Mulsant BH (July 2023). "Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial". BJPsych Open. 9 (4): e134. doi:10.1192/bjo.2023.535. PMC 10375870. PMID 37489299. Two 5- HT2A receptor antagonists – ketanserin (an antihypertensive) and risperidone (an atypical antipsychotic) – have been shown to eliminate self-reported psilocybin psychedelic effects in humans.2
  11. ^ Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, Vogel H, Hell D (December 1998). "Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action". Neuroreport. 9 (17): 3897–3902. doi:10.1097/00001756-199812010-00024. PMID 9875725.
  12. ^ Carter OL, Hasler F, Pettigrew JD, Wallis GM, Liu GB, Vollenweider FX (December 2007). "Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans". Psychopharmacology (Berl). 195 (3): 415–424. doi:10.1007/s00213-007-0930-9. PMID 17874073.
  13. ^ Quednow BB, Kometer M, Geyer MA, Vollenweider FX (February 2012). "Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers". Neuropsychopharmacology. 37 (3): 630–640. doi:10.1038/npp.2011.228. PMC 3260978. PMID 21956447.
  14. ^ Halpern, John H.; Suzuki, Joji; Huertas, Pedro E.; Passie, Torsten (2010). "Hallucinogens". Addiction Medicine. New York, NY: Springer New York. p. 1083–1098. doi:10.1007/978-1-4419-0338-9_54. ISBN 978-1-4419-0337-2.
  15. ^ Murphree, Henry (1983). "The Pharmacology of Hallucinogens". Research Advances in Alcohol and Drug Problems. Boston, MA: Springer US. p. 175–205. doi:10.1007/978-1-4613-3626-6_5. ISBN 978-1-4613-3628-0. In older work, various steroids (Bergen et al., 1960) including progesterone (Krus et aI., 1961) were reported to be effective antagonists. This has not been replicated. In other early work, some compounds initially reported to be effective were not found to be so by other workers. These include azacyclonal (Fabing, 1955) and niacin (Agnew and Hoffer, 1955).
  16. ^ Agnew N, Hoffer A (January 1955). "Nicotinic acid modified lysergic acid diethylamide psychosis". J Ment Sci. 101 (422): 12–27. doi:10.1192/bjp.101.422.12. PMID 14368207.